AMG 157

Drug Profile

AMG 157

Alternative Names: AMG-157; Anti-TSLP MAb; MEDI-9929

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Bispebjerg Hospital; Lund University; MedImmune; University of Copenhagen; University of Newcastle, Australia
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Atopic dermatitis

Most Recent Events

  • 01 Aug 2016 Phase-II clinical trials in Asthma (Treatment-experienced) in Denmark (IV) (NCT02698501)
  • 01 Jul 2016 Amgen and MedImmune completes the ALLEVIAD phase IIa trial in Atopic dermatitis in USA, Hungary, Canada, New Zealand, Germany and Australia (NCT02525094)
  • 01 May 2016 MedImmune and Amgen complete a phase I trial for Asthma (In adolescents) in Poland (NCT02512900)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top